Novel tracers and their development for the imaging of metastatic prostate cancer

Journal of Nuclear Medicine

Volumn 49, Issue 12, 2008, Pages 2031-2041

  Apolo, Andrea B ^a,b   Pandit Taskar, Neeta ^a,b   Morris, Michael J ^a,b,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Genitourinary Oncology Service   (United States)

Author keywords

11C acetate; 11C choline; 11C methionine; 18F fluorodeoxyglucose; 18F fluoro 5 dihydrotestosterone; 18F fluorocholine; Positronemission tomography; Prostate cancer

Indexed keywords

ACETIC ACID C 11; AMINO ACID; CAPROMAB PENDETIDE IN 111; CHOLINE C 11; CHOLINE F 18; FATTY ACID; FLUORINE 18; FLUORO 5ALPHA DIHYDROTESTOSTERONE F 18; FLUORODEOXYGLUCOSE F 18; MEDRONATE TECHNETIUM TC 99M; METHIONINE C 11; PHOSPHOLIPID; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG;

ARTICLE; BONE SCINTISCANNING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONSENSUS; DIAGNOSTIC IMAGING; FATTY ACID SYNTHESIS; HUMAN; ISOTOPE LABELING; METASTASIS; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MEDICINE; ONCOLOGY; OSTEOBLAST; PATIENT COMPLIANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER;

CLINICAL TRIALS AS TOPIC; HUMANS; IMAGE ENHANCEMENT; ISOTOPE LABELING; MALE; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS;

EID: 57149084500     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.050658     Document Type: Article

References (71)

1. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005;23:8253-8261.
2. Kingsley LA, Fournier PGJ, Chirgwin JM, Guise TA. Molecular biology of bone metastasis. Mol Cancer Ther. 2007;6:2609-2617.
3. Scher HI, Morris MJ, Kelly WK, Schwartz LH, Heller G. Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res. 2005;11:5223-5232.
4. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol. 2003;21:679-689.
5. Tannock IF, deWit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
6. Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol. 2002;168:2439-2443.
7. Yagoda A. Non-hormonal cytotoxic agents in the treatment of prostatic adenocarcinoma. Cancer. 1973;32:1131-1140.
8. Tannock IF. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol. 1985;3:1013-1021.
9. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17:3461-3467.
10. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148-1159.
11. Scher HI, Eisenberger M, D'Amico AV, et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 2004;22:537-556.
12. Smith PH, Bono A, Calais da Silva F, et al. Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. Cancer. 1990;66:1009-1016.
13. Johns WD, Garnick MB, Kaplan WD. Leuprolide therapy for prostate cancer: an association with scintigraphic "flare" on bone scan. Clin Nucl Med. 1990;15:485-487.
14. Pollen JJ, Shlaer WJ. Osteoblastic response to successful treatment of metastatic cancer of the prostate. AJR. 1979;132:927-931.
15. Dotan ZA, Bianco FJ Jr, Rabbani F, et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol. 2005;23:1962-1968.
16. Imbriaco M, Larson SM, Yeung HW, et al. A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. Clin Cancer Res. 1998;4:1765-1772.
17. Sabbatini P, Larson SM, Kremer A, et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol. 1999;17:948-957.
18. Morris MJ, Jia X, Larson SM, et al. Post-treatment serial bone scan index (BSI) as an outcome measure predicting for survival. In: 2008 Genitourinary Cancers Symposium Proceedings. Alexandria, VA: ASCO; 2008:189.
19. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52:637-640.
20. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81-85.
21. Wright GL Jr, Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48:326-334.
22. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59:3192-3198.
23. Morris MJ, Divgi CR, Pandit-Taskar N, et al. Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clin Cancer Res. 2005;11:7454-7461.
24. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol. 2004;22:2522-2531.
25. 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005;23:4567-4569.
26. Galsky MD, Eisenberger M, Moore-Cooper S, et al. Phase I trial of MLN2704 in patients with castrate-metastatic prostate cancer (CMPC). J Clin Oncol. 2008:2147-2154.
27. Hinkle GH, Burgers JK, Neal CE, et al. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer. 1998;83:739-747.
28. Haseman MK, Reed NL, Rosenthal SA. Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen: positron emission tomography and biopsy correlation. Clin Nucl Med. 1996;21:704-713.
29. Texter JH Jr, Neal CE. The role of monoclonal antibody in the management of prostate adenocarcinoma. J Urol. 1998;160:2393-2395.
30. Babaian RJ, Sayer J, Podoloff DA, Steelhammer LC, Bhadkamkar VA, Gulfo JV. Radioimmunoscintigraphy of pelvic lymph nodes with 111-indium-labeled monoclonal antibody CYT-356. J Urol. 1994;152:1952-1955.
31. 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients. Cancer. 1999;85:1586-1592.
32. Liu H, Moy P, Kim S, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 1997;57:3629-3634.
33. 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005;23:4591-4601.
34. Seltzer MA, Barbaric Z, Belldegrun A, et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol. 1999;162:1322-1328.
35. Morris MJ, Akhurst T, Osman I, et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology. 2002;59:913-918.
36. Sung J, Espiritu JI, Segall GM, Terris MK. Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cancer. BJU Int. 2003;92:24-27.
37. Morris MJ, Akhurst T, Larson SM, et al. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res. 2005;11:3210-3216.
38. Podo F. Tumour phospholipid metabolism. NMR Biomed. 1999;12:413-439.
39. 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer. Urol Int. 2003;70:311-315.
40. 18F]fluoro-2- deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res. 2005;11:4761-4769.
41. Scher HI, Heller G. Clinical states in prostate cancer: towards a dynamic model of disease progression. Urology. 2000;55:323-327.
42. 11C-choline PET. J Nucl Med. 2003;44:331-335.
43. 11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol. 2007;52:423-429.
44. 11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int. 2007;100:786-793.
45. 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol. 2008;54:392-401.
46. 11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:18-23.
47. 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int. 2008;102:446-451.
48. 18F-fluoride PET/CT. 2006;47:287-297.
49. Schmid DT, John H, Zweifel R, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology. 2005;235:623-628.
50. 18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging. 2006;33:1387-1398.
51. 18F- fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med. 2002;43:187-199.
52. 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res. 2001;61:110-117.
53. 18F-labeled choline analogs as oncologic PET tracers. J Nucl Med. 2001;42:1805-1814.
54. 18F-fluorocholine. J Nucl Med. 2002 2002;43:92-96.
55. 18F]fluorocholine PET/CT in the assessment of bone metastases in prostate cancer. Eur J Nucl Med Mol Imaging. 2007;34:1316-1317.
56. Cook GJ, Fogelman I. The role of positron emission tomography in skeletal disease. Semin Nucl Med. 2001;31:50-61.
57. Beheshti M, Vali R, Waldenberger P, et al. Detection of bone metastases in patients with prostate cancer by F-18 fluorocholine and F-18 fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging. 2008;35:1766-1774.
58. 11C]acetate as a tracer for noninvasive assessment of oxidative metabolism with positron emission tomography in normal, ischemic, postischemic, and hyperemic canine myocardium. Circulation. 1990;81:1594-1605.
59. Shreve P. Carbon-11 acetate PET imaging of prostate cancer. J Nucl Med. 1999;36:1595-1601.
60. 11C-acetate PET imaging of prostate cancer. J Nucl Med. 2002;43:181-186.
61. 11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin. 2003;42:25-30.
62. 11C-acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imaging. 2007;34:185-196.
63. Sandblom G, Sorensen J, Lundin N, Haggman M, Malmstrom PU. Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy. Urology. 2006;67:996-1000.
64. 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med. 2002;43:46-55.
65. 11C-methionine positron emission tomography. J Urol. 2005;173:66-69.
66. 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med. 2004;45:366-373.
67. Dehdashti F, Picus J, Michalski JM, et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging. 2005;32:344-350.
68. 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med. 2004;45:366-373.
69. 18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med. 2007;48:56-63.
70. 11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. 2007:100;786-793.
71. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer. J Clin Oncol. 2006;24:2513-2519.